Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Amgen Inc (AMGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 116,110,856
  • Shares Outstanding, K 622,278
  • Annual Sales, $ 23,747 M
  • Annual Income, $ 8,394 M
  • 60-Month Beta 1.21
  • Price/Sales 4.89
  • Price/Cash Flow 10.33
  • Price/Book 9.52

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate 3.49
  • Number of Estimates 10
  • High Estimate 3.73
  • Low Estimate 3.04
  • Prior Year 3.47
  • Growth Rate Est. (year over year) +0.58%

Price Performance

See More
Period Period Low Period High Performance
1-Month
179.01 +5.70%
on 03/08/19
192.87 -1.90%
on 03/22/19
-0.73 (-0.46%)
since 02/26/19
3-Month
179.01 +5.70%
on 03/08/19
204.33 -7.40%
on 01/18/19
+1.49 (+0.72%)
since 12/26/18
52-Week
163.31 +15.86%
on 04/02/18
210.19 -9.98%
on 09/27/18
+14.16 (+8.00%)
since 03/26/18

Most Recent Stories

More News
New Research Coverage Highlights Amgen, Alarm, Werner Enterprises, Churchill Downs, Markel, and AAR -- Consolidated Revenues, Company Growth, and Expectations for 2019

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Amgen Inc. (NASDAQ:AMGN), Alarm.com...

CHDN : 87.53 (+1.76%)
WERN : 33.37 (+1.64%)
ALRM : 63.01 (+2.16%)
AIR : 32.31 (-0.15%)
AMGN : 189.39 (+1.50%)
MKL : 991.27 (+0.56%)
S&P 500 Q4 2018 Buybacks Set 4th Consecutive Quarterly Record at $223 Billion; 2018 Sets Record $806 Billion

S&P Dow Jones Indices ("S&P DJI") announced today that preliminary Q4 2018 S&P 500® stock buybacks, or share repurchases, set a fourth consecutive record of $223.0 billion. This displaces the previous...

GOOGL : 1,195.71 (-0.14%)
AAPL : 192.04 (+1.75%)
AVGO : 299.00 (+2.34%)
CSCO : 53.34 (+1.16%)
C : 60.78 (+0.75%)
BAC : 26.98 (+0.52%)
JPM : 99.22 (+0.29%)
JNJ : 138.74 (+1.56%)
MRK : 83.15 (+0.97%)
ORCL : 53.40 (+1.25%)
AMGN : 189.39 (+1.50%)
PFE : 42.47 (+1.38%)
MSFT : 117.95 (+0.25%)
SBUX : 72.93 (+0.87%)
IBM : 140.73 (+1.11%)
WFC : 48.56 (+1.00%)
V : 155.42 (+1.56%)
SPGI : 206.20 (+0.58%)
FB : 168.44 (+1.29%)
HD : 191.49 (+0.95%)
WMT : 98.68 (+0.52%)
Spherix Global Insights' Quarterly Update on the US Migraine Prevention Market Reveals Best-In-Class Sales and Medical Affairs Support as the Driving Force Behind Teva's Ajovy Early Launch Success

With the 2018 launches of the new class of anti-calcitonin gene-related peptide (CGRP) therapies, specifically Amgen/Novartis' Aimovig, Teva's Ajovy, and Eli Lilly's Emgality, for the prevention of migraine,...

NVS : 94.75 (+1.54%)
AMGN : 189.39 (+1.50%)
Inovio Appoints Global Commercial Leader to its Board of Directors

Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today the appointment of Dr. Ann C. Miller to its Board of Directors. Dr. Miller had an outstanding marketing career launching and building blockbuster...

MRK : 83.15 (+0.97%)
INO : 3.73 (+3.04%)
AMGN : 189.39 (+1.50%)
After Yesterday's Decline of 1.85%, Amgen Inc Offers Investors Better Value

Amgen Inc (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $187.84 to a high of $191.30. Yesterday, the shares fell 1.9%, which took the trading range below the 3-day low of $189.72...

AMGN : 189.39 (+1.50%)
Look for Shares of Amgen Inc to Potentially Rebound after Yesterday's 1.85% Sell Off

Amgen Inc (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $187.84 to a high of $191.30. Yesterday, the shares fell 1.9%, which took the trading range below the 3-day low of $189.72...

AMGN : 189.39 (+1.50%)
Imago BioSciences Announces $40 Million Series B Financing Led by Omega Funds

Imago BioSciences, Inc., a clinical-stage biotechnology company developing innovative treatments for myeloid diseases, today announced a $40 million Series B financing led by Omega Funds,...

AMGN : 189.39 (+1.50%)
Amgen, Cytokinetics and Servier Announce Continuation of GALACTIC-HF Following Planned Interim Analysis

Amgen (NASDAQ: AMGN), Cytokinetics, Incorporated (NASDAQ: CYTK) and Servier today announced that the Data Monitoring Committee (DMC) for GALACTIC-HF recently completed the first planned interim analysis,...

CYTK : 8.92 (+0.90%)
AMGN : 189.39 (+1.50%)
Merchavia Expands Its Investments in Diagnostics: The Company to Invest NIS 1 Million in EFA - Engineering for All Ltd.

Merchavia Holdings and Investments (TASE: MRHL), an Israeli investment company specializing in early stage life sciences companies, announces that it is expanding its investments into the diagnostics sector....

AMGN : 189.39 (+1.50%)
Actinium Appoints Accomplished FDA and Industry Professional Mamata Gokhale, Ph.D., RAC as Vice President, Global Head of Regulatory Affairs

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM), announced today the appointment of Mamata Gokhale, Ph.D., RAC as Vice President, Global Head of Regulatory Affairs. In this role, Dr. Gokhale will...

ATNM : 0.50 (+6.38%)
AMGN : 189.39 (+1.50%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade AMGN with:

Business Summary

Amgen Inc. discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice...

See More

Key Turning Points

2nd Resistance Point 189.21
1st Resistance Point 187.90
Last Price 189.39
1st Support Level 185.16
2nd Support Level 183.73

See More

52-Week High 210.19
Fibonacci 61.8% 192.28
Last Price 189.39
Fibonacci 50% 186.75
Fibonacci 38.2% 181.22
52-Week Low 163.31

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar